You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 65 No. 5, May 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Cerebrovascular Disease
 •Dementias
 •Stroke
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Association of Plasma Total Homocysteine Levels With Subclinical Brain Injury

Cerebral Volumes, White Matter Hyperintensity, and Silent Brain Infarcts at Volumetric Magnetic Resonance Imaging in the Framingham Offspring Study

Sudha Seshadri, MD; Philip A. Wolf, MD; Alexa S. Beiser, PhD; Jacob Selhub, PhD; Rhoda Au, PhD; Paul F. Jacques, PhD; Mitsuhiro Yoshita, MD; Irwin H. Rosenberg, MD; Ralph B. D’Agostino, PhD; Charles DeCarli, MD

Arch Neurol. 2008;65(5):642-649.

Background  Elevated plasma total homocysteine (tHcy) levels have been associated with increased risk of dementia and stroke, but it is uncertain whether the mediating mechanisms are predominantly cellular, vascular, or both.

Objective  To evaluate the relationship between tHcy levels and findings at brain magnetic resonance imaging (MRI) in a community-based sample.

Design  Our sample comprised 1965 participants in the Framingham Offspring Study (1050 women; mean [SD] age, 62 [9] years) who were free of clinical stroke, dementia, or other neurologic disease affecting brain MRI and for whom at least 1 measurement of plasma tHcy level (1991-2001) and a brain MRI (1999-2002) were available. We used multivariate regression analysis to relate initial (1991-1995) and concurrent (1998-2001) plasma tHcy levels to total cerebral brain volume and lobar volumes as measures of neuronal loss and atrophy and to the presence or absence of silent brain infarcts and extensive white matter hyperintensity (log–white matter intensity ≥1 SD above the age-adjusted mean) as separate measures of vascular injury.

Results  Mean total cerebral brain volume was 78%. At MRI, 218 participants had silent brain infarcts and 250 demonstrated extensive white matter hyperintensity. Participants with a plasma tHcy level in the highest age- (–0.37%, P = .01) or sex-specific (–0.48%, P < .001) quartile had smaller total cerebral brain volumes compared with participants with lower tHcy levels. Initial tHcy levels were associated with a higher prevalence of silent brain infarct (relative risk, 1.5; 95% confidence interval, 1.1-2.1; P = .02) and concurrent tHcy levels, with smaller frontal (–0.14%, P = .001) and temporal lobar (–0.10%, P = .04) volumes. Prevalence of extensive white matter hyperintensity did not differ according to initial or concurrent plasma tHcy levels (relative risk, both 1.0; 95% confidence interval, 0.7-1.4 and 0.8-1.4, respectively).

Conclusions  Higher plasma tHcy levels are associated with smaller brain volume and the presence of silent brain infarcts at MRI, even in healthy, middle-aged adults. Thus, both cellular and vascular mechanisms may underlie the association of plasma tHcy level with brain aging, as reflected by the effects on both subclinical and overt disease.


Author Affiliations: Department of Neurology, School of Medicine (Drs Seshadri, Wolf, Beiser, and Au), Department of Biostatistics, School of Public Health (Dr Beiser), and Department of Mathematics and Statistics (Dr D’Agostino), Boston University, and Tufts Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University (Dr Selhub, Jacques, and Rosenberg), Boston, Massachusetts; and Department of Neurology, University of California, Davis, Sacramento (Drs Yoshita and DeCarli).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2008;65(5):572-573.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Advances in Vascular Cognitive Impairment
Bowler and Gorelick
Stroke 2009;40:e315-e318.
FULL TEXT  

High-Dose B Vitamin Supplementation as a Disease-Modifying Therapy in Alzheimer Disease
Viswanathan
Arch Neurol 2009;66:520-522.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.